LBA1 - Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

R Camidge, H.R Kim + Show 17 more

Open Access

https://doi.org/10.1093/annonc/mdz446

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2019
Citations: 30	License type: publisher-specific-oa

Affiliation: University of Colorado Cancer Center, Yonsei University, Samsung Medical Center, National Taiwan University, Ludwig Boltzmann Institute for COPD And Respiratory Epidemiology, Chungbuk National University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituti di Ricovero e Cura a Carattere Scientifico, Complexo Hospitalario Universitario A Coruña, Seoul National University Hospital, Pius Hospital Oldenburg, Vall d'Hebron Hospital Universitari, The Christie NHS Foundation Trust, Virginia Cancer Specialists, Yale Cancer Center, Azienda Ospedaliera Universitaria Pisana, Millennium Engineering and Integration (United States), Royal Marsden Hospital

#Baseline Brain Metastases #Expert Testimony + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA1 - Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

Full Text

Published version (

Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title

Journal

Date

Author

View more papers

Translate this paper in your preferred language
Listen to the abstract of this paper

Save
Share
Export